MarketReportsOnline.com adds Global Prostate Cancer Therapeutics Market to 2020 research report of 80 pages on the prostate cancer industry to the pharmaceuticals intelligence collection of its research store.
Pune, Maharashtra -- (SBWIRE) -- 02/13/2017 -- The prostate cancer drugs market is expected to nearly double by 2020, due to the introduction of new, more expensive drugs. Prostate Cancer is the most frequently diagnosed cancer in men. In terms of loss of life from any disease, prostate cancer ranks eleventh; and it ranks sixth in terms of cancer–related mortality in men. The prostate cancer market has a huge demand for new and novel drugs that address unmet needs such as improved survival time, less toxicity, increased progression free survival, increased effectiveness, and lower cost.
Order a copy of this "Global Prostate Cancer Therapeutics Market" research report at USD 1200 (Single User License) http://www.marketreportsonline.com/contacts/purchase.php?name=431170.
The global market for the prostate cancer therapeutics market is increasing, driven primarily by the growth in the hormone–refractory prostate cancer therapeutics market. Although, the prostate cancer market faces some hindrances such as the high cost of prostate cancer drugs, the market for prostate cancer drugs is likely to rise in the future.
Global Prostate Cancer Drugs Analysis: Zytiga was the leading prostate cancer drugs in 2014 being followed by Xtandi drugs. In prostate cancer drugs market, Leuplin and Zoladex stand at the third and fourth position respectively in 2014, while Lupron stands at the fifth position in the same year. Bayer's cancer drug Xofigo is also increasing its market share. Decapeptyl, Taxotere, Jevtana and Provenge are the other popular prostate cancer drugs in the global market.
This report titled "Global Prostate Cancer Therapeutics Market to 2020" provides a comprehensive assessment of the fast–evolving, high–growth of Prostate Cancer Therapeutics Market. This 80 page report with 35 Figures and 2 Tables analyses the Prostate Cancer Therapy Drugs Market, driving factors and challenges for prostate cancer market landscape.
Complete report available at http://www.marketreportsonline.com/431170.html.
The report covers the following:
Global Prostate Cancer – Hormonal Therapy Drugs Market
I Luteinizing Hormone–Releasing Hormone (LHRH) Antagonists
II Luteinizing Hormone–Releasing Hormone (LHRH) Analogs
2. Xtandi or MDV3100
3. Xtandi US or MDV3100
B. Global Prostate Cancer Chemotherapy Drugs Market
C. Global Prostate Cancer Immunotherapy Drugs Market– Provenge
D. Global Prostate Cancer Targeted Therapy Drugs Market– Xofigo or Alpharadin
Key Topics Covered in (http://www.marketreportsonline.com/431170-toc.html) Global Prostate Cancer Therapeutics Market:
1. Executive Summary
2. Prostate Cancer – Overview
3. Global Prostate Cancer Drugs Market
4. Global Prostate Cancer Incidence
5. Global Prostate Cancer Drugs Market Share
6. Global Prostate Cancer – Hormonal Therapy Drugs Sales & Forecast to 2020
7. Global Prostate Cancer – Chemotherapy Drugs Market
8. Global Prostate Cancer – Immunotherapy Drugs Market
9. Global Prostate Cancer – Targeted Therapy Drugs Market
10. Global Prostate Cancer Market – Driving Factors
11. Global Prostate Cancer Market – Challenges
Other Related Reports on Prostate Cancer Market:
Metastatic Hormone Refractory Prostate Cancer-Pipeline Insights, 2017: This report provides in depth insights on the pipeline drugs and their development activities around the Metastatic Hormone Refractory Prostate Cancer. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight's Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Metastatic Hormone Refractory Prostate Cancer. DelveInsight's Report also assesses the Metastatic Hormone Refractory Prostate Cancer therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.
Prostate Cancer-API Insights, 2017: The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market.
MarketReportsOnline comprises of an online library of 2,50,000 reports and in-depth market research studies of over 5000+ micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.
2nd Floor, Metropole,
Next to Inox Theatre,
Bund Garden Road,
Pune - 411001.
Tel: + 1 888 391 5441